Logo

Opaldia to Distribute Agendia s MammaPrint and CupPrint Tests in UK

Mar 30, 2006

NEW YORK, March 30 (GenomeWeb News) - Opaldia will distribute Agendia's MammaPrint and CupPrint tests in the United Kingdom, the companies said today.

 

MammaPrint uses a 70-gene profile to classify breast cancer patients as 'low' or 'high' risk for developing distant metastasis in a 10-year period.

 

The CupPrint test, meantime, is intended to identify the primary tumor in patients with cancer of unknown primary.

 

Financial terms of the agreement were not disclosed.

Breaking News
The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.